The Food and Drug Administration (FDA) has approved Halaven (eribulin mesylate; Eisai) injection for the treatment of unresectable or metastatic liposarcoma in patients who have received prior chemotherapy containing an anthracycline.
The safety and efficacy of Halaven were evaluated in study participants (n=143) with advanced liposarcoma that was unresectable, locally advanced or metastatic who had received prior chemotherapy. The study assigned patients to treatment with either Halaven or dacarbazine until disease progression or intolerability.
Median overall survival for patients receiving Halaven was 15.6 months vs. 8.4 months for patients receiving dacarbazine. The most commonly reported side effects were fatigue, nausea, alopecia, constipation, peripheral neuropathy, abdominal pain, and pyrexia. This is the first drug approved for patients with liposarcoma that has shown an improvement in survival time.
Halaven, a non-taxane microtubule dynamics inhibitor, is already indicated for the treatment of metastatic breast cancer in patients who have previously received at least two chemotherapeutic regimens for metastatic disease. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting.
Halaven is available as 0.5mg/mL strength solution in 2mL single-use vials.
For more information call (877) 873-4724 or visit Halaven.com.